Klaria Pharma Holding AB (publ) (“Klaria” or the “Company”) has announced its intention to resolve on a rights issue of shares amounting to approximately SEK 65.1 million before issue costs (the “Rights Issue”). The proceeds from the Rights Issue, after deduction of issue costs, are intended to repay existing loans including interest payments, cover the Company's working capital needs and finance production and support for launch activities. The Company has received subscription commitments totaling approximately SEK 2.2 million, corresponding to approximately 3.4 percent of the Rights Issue. Existing and external investors have provided guarantee commitments totaling approximately SEK 33.8 million, corresponding to approximately 51.9 percent of the Rights Issue. The Board of Directors has also decided to propose a directed convertible issue to a number of existing and external investors of SEK 9.7 million, of which SEK 6 million will be paid in cash and SEK 3.7 million will be paid by set-off.

Background and motive
Over the past few years, Klaria has made significant progress in the development and commercialization of its patented drug delivery platform - an alginate-based oral film that enables fast and effective drug delivery via the oral mucosa. This technology forms the basis of the Company's lead product, Sumatriptan Alginate Film (’’SAF’’), which targets the rapidly growing global migraine market.

In 2024, Klaria initiated an active commercialization phase together with its commercial partners, with the aim of launching SAF in a number of priority markets. In the first quarter of 2025, Klaria signed its first commercial agreement with the reputable and fast-growing pharmaceutical company CNX Therapeutics Ltd (’’CNX’’). The regulatory process for the product is in the final phase or has already been completed in several countries, which means that revenues from product sales are expected to start to be realized gradually during 2025.

To enable this commercialization and to meet future financial commitments, Klaria has decided to carry out the Share Issues. The proceeds from the Share Issues, after deduction of issue costs, are intended to repay existing loans including interest payments, cover the Company's working capital needs and finance production and support for launch activities.

About Klaria Pharma Holding
Klaria Pharma Holding is active in the pharmaceutical industry. Today, the business is focused on commercialising solutions in the therapeutic areas of migraine and cancer-related pain. The technology is based on the company's drug-delivery platform, where the product consists of alginate-based polymer film. The film is attached to the patient's oral mucosa, enabling the distribution of drugs in the body. The head office is located in Uppsala.

Corpura acted as Sole Coordinator and Bookrunner in connection with the capital raise.

For more information contact:
‍Jonatan Andersson
Phone: +46 (0)70-508 00 51
‍Email: jonatan.andersson@corpura.se

‍